These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30286820)

  • 1. Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study.
    Wang HY; Jiao QP; Chen SY; Sheng J; Jiang H; Lu J; Zheng SB; Fang NY
    Am J Med Sci; 2018 Sep; 356(3):254-261. PubMed ID: 30286820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
    Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J
    Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
    Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
    Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits.
    Gámez R; Máz R; Arruzazabala ML; Mendoza S; Castaño G
    Drugs R D; 2005; 6(1):11-9. PubMed ID: 15806713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, double-blind, placebo-controlled, parallel-group, comparative study.
    Castaño G; Más R; Fernández J; López E; Illnait J; Fernández L; Mesa M
    Curr Ther Res Clin Exp; 2003 Sep; 64(8):522-37. PubMed ID: 24944402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
    Castaño G; Más R; Fernández L; Illnait J; Mendoza S; Gámez R; Fernández J; Mesa M
    Drugs Exp Clin Res; 2005; 31 Suppl():31-44. PubMed ID: 16444910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
    Castaño G; Fernández L; Mas R; Illnait J; Fernández J; Mesa M; Alvarez E; Lezcay M
    Int J Clin Pharmacol Res; 2002; 22(2):55-66. PubMed ID: 12503776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant use of policosanol and beta-blockers in older patients.
    Castaño G; Mas R; Gámez R; Fernández J; Illnait J; Fernández L; Mendoza S; Mesa M; Gutiérrez JA; López E
    Int J Clin Pharmacol Res; 2004; 24(2-3):65-77. PubMed ID: 15689053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study.
    Castaño G; Más R; Gámez R; Fernández L; Illnait J
    Angiology; 2004; 55(4):361-71. PubMed ID: 15258682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.
    McKenney J; Jones M; Abby S
    Curr Med Res Opin; 2005 Sep; 21(9):1403-12. PubMed ID: 16197659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials.
    Gong J; Qin X; Yuan F; Hu M; Chen G; Fang K; Wang D; Jiang S; Li J; Zhao Y; Huang Z; Dong H; Lu F
    Mol Nutr Food Res; 2018 Jan; 62(1):. PubMed ID: 28730734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia.
    Castaño G; Más R; Fernández JC; Fernández L; Illnait J; López E
    Drugs R D; 2002; 3(3):159-72. PubMed ID: 12099160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.